医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Aroa Biosurgery and Hydrofera Team up in US

2018年05月02日 PM07:00
このエントリーをはてなブックマークに追加


 

MANCHESTER, Conn. & AUCKLAND, New Zealand

New Zealand biomedical company Aroa Biosurgery and United States medical products company Hydrofera are launching Appulse in North America.

The two companies have recently bought back their wound care businesses from Hollister Inc.

Brian Ward, CEO of Aroa Biosurgery, says the company’s Endoform wound care technology and Hydrofera Blue are complementary.

“We have both been successfully represented by Hollister, but with Hollister’s decision to divest portions of its wound care business back to the technology developers, it gives us the opportunity to now grow the businesses ourselves.”

Tom Drury, CEO of Hydrofera, says: “On June 1 we will launch Appulse and most of the Hollister sales team for Endoform and Hydrofera Blue will continue to represent both products.

“This will help ensure the same level of service to patients, clinicians and distribution partners.”

Endoform is a proprietary extracellular matrix (ECM) biomaterial, which contains a collagen scaffold and important secondary molecules to support healing.

Endoform Dermal Template was launched in the US in 2013 for the treatment of acute and chronic wounds after obtaining US Food & Drug Administration (FDA) clearance. Since then Endoform has become established as a leading product for treating diabetic and venous ulcers and been used in more than 2.5 million treatments.

Hydrofera, LLC produces a unique line of antibacterial wound dressings, utilizing its proprietary PVA and polyurethane foam technology in combination with two natural organic pigments. This unique combination of two technology platforms yields a line of advanced wound dressings that improve patient outcomes and lower treatment costs.

About Aroa Biosurgery:
Aroa is a private, venture funded soft-tissue repair company that develops and manufactures medical products to improve healing. Its products are developed from their Endoform™ platform, a novel extracellular matrix biomaterial. The company strives to improve patient outcomes and provide better healing, every day, everywhere for everybody. www.aroabio.com

About Hydrofera, LLC
Hydrofera, LLC, is owned by a group of investors led by Tom Drury, one of the founders of Hydrofera Blue products. The company develops and manufactures Polyvinyl Alcohol (PVA) foam products for medical applications. Headquartered in Manchester, Connecticut, Hydrofera LLC serves customers in the United States and Canada with its award-winning portfolio of Hydrofera Blue products.

View source version on businesswire.com: https://www.businesswire.com/news/home/20180502005672/en/

CONTACT

For information contact:
Aroa Biosurgery Ltd
Brian
Ward, +64 21 727646
brian.ward@aroabio.com
www.arobio.com
or
Hydrofera
LLC
Tom Drury, +1 8609307819
tomd@hyrof.com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • City of Hope与Israelita Albert Einstein签署协议以推动拉美地区的癌症治疗
  • Humanigen Announces Closing of Public Offering of Common Stock
  • Masimo O3®を使用してCOVID-19患者の脳酸素化に及ぼす換気補助療法の影響を追究した研究
  • CoVIg-19プラズマ・アライアンス、COVID-19治療薬候補の高度免疫グロブリン製剤を評価するためにNIHが実施した臨床試験のトップライン結果を発表
  • CoVIg-19血浆联盟公布NIH发起的在研药物COVID-19超免疫球蛋白临床试验的顶线结果